In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy

Clinical Cancer Research

Volumn 12, Issue 18, 2006, Pages 5543-5549

  Foster, Paul A ^a   Newman, Simon P ^a   Chander, Surinder K ^a   Stengel, Chloe ^a   Jhalli, Roma ^a   Woo, Lawrence L W ^b   Potter, Barry V L ^b   Reed, Michael J ^a   Purohit, Atul ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BATH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; ESTERASE INHIBITOR; ESTRADIOL; MESSENGER RNA; STERYL SULFATASE; STX 213; STX 64; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL STRAIN MCF 7; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HORMONE DEPENDENCE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TREATMENT OUTCOME; TUMOR VOLUME;

ANIMALS; AZASTEROIDS; BREAST NEOPLASMS; ENZYME INHIBITORS; ESTRADIOL; FEMALE; HUMANS; LIVER; MICE; MICE, NUDE; MODELS, BIOLOGICAL; NEOPLASMS, HORMONE-DEPENDENT; RATS; RATS, WISTAR; RNA, MESSENGER; STERYL-SULFATASE; TISSUE DISTRIBUTION; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33749331848     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0632     Document Type: Article

References (38)

1. Cole MP, Jones CTA, Todd IDH. A new antiestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46,474. Br J Cancer 1971;25:270-5.
2. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003;48:2431-42.
3. Reed MJ, Purohit A, Woo LWL, Potter BVL. The development of steroid sulphatase inhibitors. Endocr Relat Cancer 1996;3:9-23.
4. Taylor RE, Powles TJ, Humphreys J, et al. Effects of endocrine therapy on steroid-receptor content of breast cancer. Br J Cancer 1982;45:80-5.
5. Reed MJ, Hutton JD, Baxendale PM, James VH, Jacobs HS, Fisher RP. The conversion of androstenedione to oestrone and production of oestrone in women with endometrial cancer. J Steroid Biochem 1979; 11:905-11.
6. Falany JL, Falany CN. Expression of cytosolic sulfo-transferases in normal mammary epithelial cells and breast cancer cell lines. Cancer Res 1996;56:1551-5.
7. Falany JL, Macrina N, Falany CN. Regulation of MCF-7 breast cancer cell growth by p-estradiol sulfonation. Breast Cancer Res Treat 2002;74:167-76.
8. Purohit A, Riaz AA, Ghilchik MW, Reed MJ. The origin of oestrone sulphate in normal and malignant breast tissues in postmenopausal women. Horm Metab Res 1992;24:532-6.
9. Reed MJ, Purohit A, Woo LWL, Newman SP, Potter BVL. Steroid sulfatase: molecular biology, regulation, and inhibition. Endocr Rev 2005;26:171-202.
10. Bonney RC, Reed MJ, Davidson K, Beranek PA, James VHT. The relationship between 17β-hydroxysteroid dehydrogenase activity and oestrogen concentrations in human breast tumours and in normal breast tissue. Clin Endocrinol (Oxf) 1983;19:727-39.
11. Pasqualini JR, Chetrite G, Blacker C, et al. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J Clin Endocrinol Metab 1996;81:1460-4.
12. Lipton A, Santen RJ, Santner SJ, Harvey HA, Sanders SI, Matthews YL. Prognostic value of breast cancer aromatase. Cancer 1992;70:1951-5.
13. Evans TR, Rowlands MG, Law M, Coombes RC. Intratumoral oestrone sulphatase activity as a prognostic marker in human breast carcinoma. Br J Cancer 1994;69:555-61.
14. Lonning PE, Dowsett M, Powles TJ. Postmenopausal estrogen synthesis and metabolism: alteration caused by aromatase inhibitors used for the treatment of breast cancer. J Steroid Biochem 1990; 35:355-66.
15. Evans TR, Rowlands MG, Silva MC, Law M, Coombes RC. Prognostic significance of aromatase and estrone sulfatase enzymes in human breast cancer. J Steroid Biochem Mol Biol 1993;44:583-7.
16. James VHT, McNeill JM, Lai LC, Newton CJ, Ghilchik MW, Reed MJ. Aromatase activity in normal breast and breast tumor tissue: in vivo and in vitro studies. Steroids 1987;50:269-79.
17. Santner SJ, Feil RD, Santen RJ. In situ estrogen production via estrone sulphatase pathway in breast tumors: relative importance versus aromatase pathway. J Clin Endocrinol Metab 1984;54:29-33.
18. Utsumi T, Yoshimura N, Takeuchi S, et al. Elevated steroid sulfatase expression in breast cancers. J Steroid Biochem Mol Biol 2000;73:141-5.
19. Utsumi T, Yoshimura N, Maruta M, et al. Significance of steroid sulfatase expression in human breast cancer. Breast Cancer 1999;6:298-300.
20. Miyoshi Y, Ando A, Hasegawa S, et al. High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer. Clin Cancer Res 2003;9:2288-93.
21. Poulin R, Labrie F. Stimulation of cell proliferation and estrogenic response by adrenal C19-δ 5-steroids in the ZR-75-1 human breast cancer cell line. Cancer Res 1986;46:4933-7.
22. Dauvois S, Danielian PS, White R, Parker MG. Anti-estrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci U S A 1992;89:4037-41.
23. Thijssen JH. Local biosynthesis and metabolism of oestrogens in the human breast. Maturitas 2004;49: 25-33.
24. James MR, Skaar TC, Lee RY, et al. Constitutive expression of the steroid sulfatase gene supports the growth of MCF-7 human breast cancer cells in vitro and in vivo. Endocrinology 2001;142:1497-505.
25. Purohit A, Woo LWL, Potter BVL, Reed MJ. In vivo inhibition of estrone sulfatase activity and growth of nitrosomethylurea-induced mammary tumors by 667 COUMATE. Cancer Res 2000;60:3394-6.
26. Howarth NM, Purohit A, Reed MJ, Potter BVL. Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential. J Med Chem 1994;37: 219-21.
27. Woo LWL, Purohit A, Malini B, Reed MJ, Potter BVL. Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates. Chem Biol 2000;7:773-91.
28. Malini B, Purohit A, Ganeshapillai D, Woo LWL, Potter BVL, Reed MJ. Inhibition of steroid sulphatase activity by tricyclic coumarin sulphamates. J Steroid Biochem Mol Biol 2000;75:253-8.
29. Stanway S, Purohit A, Woo LWL, et al. Phase I study of STX64 (667 Coumate) in breast cancer: the first study of a steroid sulfatase inhibitor. Clin Cancer Res 2006;12:1585-92.
30. Fischer DS, Woo LWL, Mahon MF, Purohit A, Reed MJ, Potter BVL. D-ring modified estrone derivatives as novel potent inhibitors of steroid sulfatase. Bioorg Med Chem 2003;11:1685-700.
31. Purohit A, Williams GJ, Roberts CJ, Potter BVL, Reed MJ. In vivo inhibition of oestrone sulphatase and dehydroepiandrosterone sulphatase by oestrone-3-O-sulphamate. Int J Cancer 1995;63:106-11.
32. Fischer DS, Chander SK, Woo LWL, et al. Novel D-ring modified steroid derivatives as potent, non-estrogenic, steroid sulfatase inhibitors with in vivo activity. J Steroid Biochem Mol Biol 2003;84:343-9.
33. Seibert K, Shafie SM, Triche TJ, et al. Clonal variation of MCF-7 breast cancer cells in vitro and in athymic nude mice. Cancer Res 1983;43:2223-39.
34. Brunner N, Spang-Thomsen M, Vindelov L, Wolff J, Engelholm SA. Effect of tamoxifen on the receptor-positive T61 and the receptor-negative T60 human breast carcinomas grown in nude mice. Eur J Cancer Clin Oncol 1985;21:1349-54.
35. Miyoshi Y, Ando A, Shiba E, Taguchi T, Tamaki Y, Noguchi S. Involvement of up-regulation of 17p-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers. Int J Cancer 2001;94:685-9.
36. Leung JY, Kolligs FT, Wu R, et al. Activation of AXIN2 expression by p-catenin-Tcell factor. A feedback repressor pathway regulating Wnt signaling. J Biol Chem 2002;277:21657-65.
37. Yue W, Brodie A. MCF-7 human breast carcinomas in nude mice as a model for evaluating aromatase inhibitors. J Steroid Biochem Mol Biol 1993;44:671-3.
38. Yue W, Zhou D, Chen S, Brodie A. A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res 1994;54:5092-5.